Medindia

X

Glenmark’s Patent Plea For Skin Care Drug Rejected By The US District Court Of Delaware

by Lakshmi Darshini on  July 29, 2015 at 7:05 PM Corporate News   - G J E 4
Pharmaceutical company Glenmark's Finacea, generic skin care drug, that was under patent litigation, violates patent of Bayer.
Glenmark’s Patent Plea For Skin Care Drug Rejected By The US District Court Of Delaware
Glenmark’s Patent Plea For Skin Care Drug Rejected By The US District Court Of Delaware
Advertisement

The US District Court of Delaware at Wilmington, has said that claims of Bayer Healthcare Pharmaceuticals Inc, Intendis and Intraserv's litigation for Bayer's Finacea, a gel for treating the common skin condition rosacea against Glenmark is valid.

Advertisement
The court came to the conclusion that Glenmark had infringed the "070 patent" of the plaintiffs and "that asserted claims of 070 patents are valid" and ordered the judgment in favor of Bayer and other plaintiffs.

The companies had filed a case against Glenmark in 2013 after it had filled an Abbreviated New Drug Application (ANDA) seeking to market a generic azelaic acid hydrogel in 2012.

Bayer Healthcare Pharmaceuticals Inc is the holder of approved New Drug Application for Finacea gel.

Glenmark currently employs over 10,400 people in over 80 countries. It has 14 manufacturing facilities in four countries and has 6 R&D centers.

Source: PTI
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All